Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Kymera rapeutics | Rare Historical Photos

Why Kymera Therapeutics Stock Is Gaining Wednesday

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell Lymphoma (PTCL).

Benzinga · Jun 1, 2022

Analyst Ratings for Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Benzinga · Jun 1, 2022

Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying

Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades.

Benzinga · Jun 1, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Kymera Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter.

Benzinga · May 13, 2022

Executives Buy Around $141M Of 4 Stocks

Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades.

Benzinga · May 10, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · May 3, 2022

Kymera Therapeutics: Q1 Earnings Insights

Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 3, 2022

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Benzinga · Apr 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Benzinga · Apr 28, 2022

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET

Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this link to access the live webcast.

Benzinga · Apr 21, 2022

Coverage From

Benzinga

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.